Matinas BioPharma Holdings, Inc. 8-K

What Happened

• On April 2, 2026 Matinas BioPharma Holdings, Inc. announced it received a written notice from the NYSE American that it does not meet the exchange’s continued listing standards because it has reported losses in each of the five most recent fiscal years. As of December 31, 2025 the company reported stockholders’ equity of $4.83 million.
• The NYSE American rules cited (Section 1003(a)(i)-(iii)) set minimum equity thresholds of $2.0M, $4.0M or $6.0M depending on the number of years of losses. The notice states the company is not currently eligible for an exemption and must submit a plan to regain compliance by May 2, 2026. If accepted, the company may be given up to an 18‑month “cure period” with periodic (including quarterly) monitoring; if not accepted, delisting proceedings would begin. Matinas issued a press release on April 3, 2026 about the notice.

Key Details

• Stockholders’ equity: $4.83 million (as of 12/31/2025).
• Reported losses in the five most recent fiscal years (through 2025).
• Plan to regain compliance due to NYSE American by May 2, 2026.
• If NYSE accepts the plan, the company could have up to an 18‑month cure period; if not, delisting proceedings may commence. Shares remain listed and trading for now.

Why It Matters

• A NYSE notice of non‑compliance is a material listing risk: if the company cannot demonstrate a credible plan and regain compliance, it could face delisting, which typically reduces liquidity and can depress share price.
• For now, there is no immediate change to the company’s listing, operations, or SEC reporting, but investors should monitor the company’s plan submission, NYSE responses, and subsequent filings for updates on compliance progress or potential delisting actions.